NASDAQ:TECH Bio-Techne (TECH) Stock Forecast, Price & News $78.17 -1.12 (-1.41%) (As of 10:59 AM ET) Add Compare Share Share Today's Range$78.00▼$79.4050-Day Range$73.76▼$85.9852-Week Range$68.00▼$99.33Volume142,981 shsAverage Volume1.03 million shsMarket Capitalization$12.31 billionP/E Ratio46.81Dividend Yield0.41%Price Target$104.45 ProfileProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Bio-Techne MarketRank™ ForecastAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside31.7% Upside$104.45 Price TargetShort InterestHealthy1.91% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainability-1.82Upright™ Environmental ScoreNews Sentiment0.70Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth19.19%From $1.72 to $2.05 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.73 out of 5 starsMedical Sector52nd out of 986 stocksBiological Products, Except Diagnostic Industry7th out of 163 stocks 3.4 Analyst's Opinion Consensus RatingBio-Techne has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $104.45, Bio-Techne has a forecasted upside of 31.7% from its current price of $79.29.Amount of Analyst CoverageBio-Techne has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.91% of the outstanding shares of Bio-Techne have been sold short.Short Interest Ratio / Days to CoverBio-Techne has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bio-Techne has recently increased by 7.91%, indicating that investor sentiment is decreasing significantly. Previous Next 1.7 Dividend Strength Dividend YieldBio-Techne has a dividend yield of 0.39%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthBio-Techne has only been increasing its dividend for 1 years.Dividend CoverageThe dividend payout ratio of Bio-Techne is 19.16%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Bio-Techne will have a dividend payout ratio of 15.61% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBio-Techne has received a 60.58% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antibodies", "Biochemical assay kits", and "Laboratory reagents" products. See details.Environmental SustainabilityThe Environmental Impact score for Bio-Techne is -1.82. Previous Next 2.1 News and Social Media Coverage News SentimentBio-Techne has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Bio-Techne this week, compared to 6 articles on an average week.Search InterestOnly 11 people have searched for TECH on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Bio-Techne to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bio-Techne insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.45% of the stock of Bio-Techne is held by insiders.Percentage Held by InstitutionsOnly 23.92% of the stock of Bio-Techne is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Bio-Techne are expected to grow by 19.19% in the coming year, from $1.72 to $2.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bio-Techne is 47.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.59.Price to Earnings Ratio vs. SectorThe P/E ratio of Bio-Techne is 47.48, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 88.11.Price to Earnings Growth RatioBio-Techne has a PEG Ratio of 3.67. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBio-Techne has a P/B Ratio of 7.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bio-Techne (NASDAQ:TECH) StockBio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. TRead More Receive TECH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter. Email Address TECH Stock News HeadlinesJune 4, 2023 | americanbankingnews.comAnalysts Set Bio-Techne Co. (NASDAQ:TECH) Target Price at $104.45June 1, 2023 | finance.yahoo.comImmunoassay Global Market Report 2023June 9, 2023 | Edge On The Street (Ad)All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A SupercycleMore automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...June 1, 2023 | finance.yahoo.comBIO-TECHNE SUCCESSFUL ON CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTECMay 31, 2023 | msn.comThis Favorable Sign Appears On Bio-Techne's ChartMay 29, 2023 | finance.yahoo.comShould You Hold Bio-Techne Corp. (TECH)?May 28, 2023 | fool.comBio-Techne (NASDAQ: TECH)May 25, 2023 | finance.yahoo.comBIO-TECHNE TO PRESENT AT THE 2023 JEFFERIES HEALTHCARE CONFERENCEJune 9, 2023 | Edge On The Street (Ad)Graphite versus Lithium - What Investors Should KnowOver 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.May 22, 2023 | americanbankingnews.comBio-Techne (NASDAQ:TECH) Research Coverage Started at StockNews.comMay 19, 2023 | americanbankingnews.comQ3 2024 EPS Estimates for Bio-Techne Co. Cut by Analyst (NASDAQ:TECH)May 18, 2023 | msn.comBio-Techne Corporation: Long-Term Quality, But At A PriceMay 18, 2023 | finance.yahoo.comEXOSOME DIAGNOSTICS RELEASES INTERIM RESULTS FROM CLINICAL STUDY OF PROSTATE CANCER RISK TESTMay 17, 2023 | marketwatch.comSerum-Free Freezing Media Market Size: Growth Dynamics from 2023 to 2031May 16, 2023 | finance.yahoo.comThose who invested in Bio-Techne (NASDAQ:TECH) five years ago are up 118%May 16, 2023 | finance.yahoo.comBIO-TECHNE COMMERCIALIZES RNASCOPE SPATIAL BIOLOGY WORKFLOW FOR THE STANDARD BIOTOOLS HYPERION IMAGING SYSTEMMay 16, 2023 | americanbankingnews.comFY2023 EPS Estimates for Bio-Techne Co. (NASDAQ:TECH) Cut by SVB LeerinkMay 15, 2023 | marketwatch.comApoptosis Market Growth and Revenue by 2030May 12, 2023 | finance.yahoo.comBIO-TECHNE TO PRESENT AT THE 2023 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCEMay 11, 2023 | marketwatch.comHow the price action of Bio-techne Corp Common Stock ($TECH) is used to our AdvantageMay 10, 2023 | finance.yahoo.comBIO-TECHNE ANNOUNCES LAUNCH OF KAPPA AND LAMBDA RNAscope ISH PROBES AS ANALYTE SPECIFIC REAGENTS (ASRs) FOR THE DETECTION OF IMMUNOGLOBULIN KAPPA AND LAMBDA LIGHT CHAINS mRNAMay 8, 2023 | americanbankingnews.comBio-Techne Co. (NASDAQ:TECH) Receives $104.45 Consensus Price Target from AnalystsMay 6, 2023 | americanbankingnews.comHead to Head Comparison: Aziyo Biologics (NASDAQ:AZYO) vs. Bio-Techne (NASDAQ:TECH)May 4, 2023 | americanbankingnews.comRobert W. Baird Boosts Bio-Techne (NASDAQ:TECH) Price Target to $100.00May 2, 2023 | finance.yahoo.comHere’s Why Bio-Techne Corporation (TECH) Declined in Q1May 2, 2023 | finance.yahoo.comBIO-TECHNE TO PRESENT AT THE BofA SECURITIES 2023 HEALTH CARE CONFERENCEMay 1, 2023 | americanbankingnews.comBio-Techne (TECH) to Release Quarterly Earnings on WednesdaySee More Headlines TECH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TECH Company Calendar Last Earnings5/03/2023Ex-Dividend for 5/26 Dividend5/12/2023Dividend Payable5/26/2023Today6/09/2023Fiscal Year End6/30/2023Next Earnings (Estimated)8/03/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:TECH CUSIP87837710 CIK842023 Webwww.bio-techne.com Phone(612) 379-8854Fax612-656-4400Employees3,000Year Founded1981Price Target and Rating Average Stock Price Forecast$104.45 High Stock Price Forecast$120.00 Low Stock Price Forecast$88.00 Forecasted Upside/Downside+31.7%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$1.67 Trailing P/E Ratio47.48 Forward P/E Ratio46.10 P/E Growth3.69Net Income$272.05 million Net Margins24.15% Pretax Margin29.32% Return on Equity15.31% Return on Assets11.42% Debt Debt-to-Equity Ratio0.20 Current Ratio4.04 Quick Ratio2.84 Sales & Book Value Annual Sales$1.12 billion Price / Sales11.11 Cash Flow$2.37 per share Price / Cash Flow33.42 Book Value$10.84 per share Price / Book7.31Miscellaneous Outstanding Shares157,437,000Free Float150,431,000Market Cap$12.48 billion OptionableOptionable Beta1.26 Social Links Key ExecutivesCharles R. KummethPresident, Chief Executive Officer & DirectorJames T. HippelChief Financial OfficerShane BohnenSecretary, Senior Vice President & General CounselBrenda S. EversonChief Human Resources Officer & Senior VPRobert M. GavinVice President-Corporate DevelopmentKey CompetitorsQiagenNYSE:QGENRepligenNASDAQ:RGENNeurocrine BiosciencesNASDAQ:NBIXExelixisNASDAQ:EXELCRISPR TherapeuticsNASDAQ:CRSPView All CompetitorsInsiders & InstitutionsProShare Advisors LLCBought 8,420 shares on 5/26/2023Ownership: 0.019%Toroso Investments LLCBought 174 shares on 5/23/2023Ownership: 0.003%Ameriprise Financial Inc.Bought 566,681 shares on 5/22/2023Ownership: 1.933%Power Corp of CanadaBought 18,035 shares on 5/19/2023Ownership: 0.024%New York State Common Retirement FundSold 5,500 shares on 5/18/2023Ownership: 0.410%View All Insider TransactionsView All Institutional Transactions TECH Stock - Frequently Asked Questions Should I buy or sell Bio-Techne stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TECH shares. View TECH analyst ratings or view top-rated stocks. What is Bio-Techne's stock price forecast for 2023? 9 brokerages have issued 12-month price targets for Bio-Techne's stock. Their TECH share price forecasts range from $88.00 to $120.00. On average, they predict the company's share price to reach $104.45 in the next year. This suggests a possible upside of 31.7% from the stock's current price. View analysts price targets for TECH or view top-rated stocks among Wall Street analysts. How have TECH shares performed in 2023? Bio-Techne's stock was trading at $82.88 at the beginning of the year. Since then, TECH stock has decreased by 4.3% and is now trading at $79.29. View the best growth stocks for 2023 here. When is Bio-Techne's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our TECH earnings forecast. How were Bio-Techne's earnings last quarter? Bio-Techne Co. (NASDAQ:TECH) released its earnings results on Wednesday, May, 3rd. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.05. The biotechnology company earned $294.15 million during the quarter, compared to analyst estimates of $298.55 million. Bio-Techne had a net margin of 24.15% and a trailing twelve-month return on equity of 15.31%. The business's revenue for the quarter was up 1.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.49 earnings per share. How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne? Bio-Techne declared a quarterly dividend on Wednesday, May 3rd. Investors of record on Monday, May 15th will be given a dividend of $0.08 per share on Friday, May 26th. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Friday, May 12th. Read our dividend analysis for TECH. What ETFs hold Bio-Techne's stock? ETFs with the largest weight of Bio-Techne (NASDAQ:TECH) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), American Century Mid Cap Growth Impact (MID), VanEck Biotech ETF (BBH), BlackRock Future Innovators ETF (BFTR), Putnam BioRevolution ETF (SYNB), Invesco S&P 500 Equal Weight Health Care ETF (RYH) and WisdomTree BioRevolution Fund (WDNA). Is Bio-Techne a good dividend stock? Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.39%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 19.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 15.61% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for TECH. When did Bio-Techne's stock split? Bio-Techne shares split on the morning of Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly created shares were distributed to shareholders after the market closes on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. What is Charles Kummeth's approval rating as Bio-Techne's CEO? 95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees. What other stocks do shareholders of Bio-Techne own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA). What is Bio-Techne's stock symbol? Bio-Techne trades on the NASDAQ under the ticker symbol "TECH." Who are Bio-Techne's major shareholders? Bio-Techne's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.17%), State Street Corp (3.99%), Select Equity Group L.P. (3.58%), Neuberger Berman Group LLC (2.58%), Geode Capital Management LLC (2.38%) and Brown Capital Management LLC (2.07%). Insiders that own company stock include Alpna Seth, Brenda S Furlow, Brenda S Furlow, Charles R Kummeth, Charles R Kummeth, Glenn Hedde, James Hippel, John L Higgins, Kim Kelderman, Norman David Eansor, Robert V Baumgartner and Roeland Nusse. View institutional ownership trends. How do I buy shares of Bio-Techne? Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bio-Techne's stock price today? One share of TECH stock can currently be purchased for approximately $79.29. How much money does Bio-Techne make? Bio-Techne (NASDAQ:TECH) has a market capitalization of $12.48 billion and generates $1.12 billion in revenue each year. The biotechnology company earns $272.05 million in net income (profit) each year or $1.67 on an earnings per share basis. How many employees does Bio-Techne have? The company employs 3,000 workers across the globe. Does Bio-Techne have any subsidiaries? The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.Read More How can I contact Bio-Techne? Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The official website for the company is www.bio-techne.com. The biotechnology company can be reached via phone at (612) 379-8854, via email at ir@bio-techne.com, or via fax at 612-656-4400. This page (NASDAQ:TECH) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bio-Techne Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.